Cases & Deals

  • Home
  • Practices
  • Vifor Pharma invests $50 million in Cara Therapeutics

Share

Vifor Pharma invests $50 million in Cara Therapeutics

August 2021

Client(s) Vifor Pharma

Jones Day advised Vifor (International) Ltd., part of Vifor Pharma Group, a global pharmaceutical company, on its $50 million investment in Cara Therapeutics, Inc., a clinical stage biopharmaceutical company, as part of a licensing agreement for the commercialization of a drug used to treat chronic kidney disease-associated pruritus in the U.S. dialysis market.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.